Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Corcept Therapeutics Fell as Much as 13.7% Today

By Maxx Chatsko – Updated Apr 9, 2019 at 5:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced preliminary full-year 2018 results that fell below Wall Street's expectations.

What happened

Shares of Corcept Therapeutics (CORT 1.74%) fell nearly 14% today after the company announced preliminary full-year 2018 results. The pharma company reported full-year revenue of $251.2 million, including fourth-quarter 2018 revenue of $66.8 million. Both were below the consensus estimates on Wall Street of $254.8 million and $70.4 million, respectively, according to numbers compiled by Yahoo! Finance.

Management said it expects full-year 2019 revenue of $285 million to $315 million, which would represent a sharp slowdown in top-line growth driven by its lone drug, Korlym, a treatment for Cushing's syndrome. However, the business is comfortably profitable and exited 2018 with nearly $207 million in cash and investments.

Check out the latest Corcept earnings call transcript.

As of 12:01 p.m. EST, the stock had settled to a 9.4% loss.

Lines capped with arrows pointing down at a 45-degree angle drawn on a chalkboard.

Image source: Getty Images.

So what

As far as individual investors are concerned, Wall Street estimates should never really be given too much weight. Remember, they're essentially models in spreadsheets based on estimated guesses made after talking to management and doctors (if analysts even do that). That said, there are still two things investors should be watching at Corcept Therapeutics.

First, revenue growth for Korlym is indeed slowing down. Full-year 2018 revenue grew 58% from the year-ago period, but fourth-quarter 2018 revenue grew just 25% from the prior-year period. That means product revenue was growing much more quickly in the beginning of last year than at the end. Achieving the high end of 2019 revenue guidance would represent growth of 25% from 2018.

Second, Corcept Therapeutics was recently the subject of an investigation by the Southern Investigative Reporting Foundation (SIRF) that uncovered questionable safety and efficacy data for Korlym, among other red flags for the business. The allegations should give any investor pause and, quite frankly, suggest the stock is much too risky to own.

Now what

Corcept Therapeutics sports a market cap of $1.2 billion after a rough week. While that's relatively cheap on a sales basis, there are some notable red flags and sources of uncertainty that investors cannot dismiss. Simply put, the fact that the business whiffed on Wall Street estimates is not the main story to follow.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corcept Therapeutics Stock Quote
Corcept Therapeutics
$26.84 (1.74%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.